Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_4
2
40%
Ph phase_3
1
20%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (40.0%)
Phase 31 (20.0%)
Phase 42 (40.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

Aggrenox Prevention of Access Stenosis

NCT00067119
completedphase_1

Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers

NCT02278302
completedphase_4

Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH

NCT02251184
completedphase_1

Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers

NCT02226926
completedphase_4

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

NCT00153062

Clinical Trials (5)

Showing 5 of 5 trials
NCT00067119Phase 3

Aggrenox Prevention of Access Stenosis

Completed
NCT02278302Phase 1

Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers

Completed
NCT02251184Phase 4

Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH

Completed
NCT02226926Phase 1

Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers

Completed
NCT00153062Phase 4

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5